Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma

Journal of Clinical Oncology

Volumn 25, Issue 27, 2007, Pages 4293-4297

  Zinzani, Pier Luigi ^a,b   Musuraca, Gerardo ^a   Toni, Monica ^a   Stefoni, Vittorio ^a   Marchi, Enrica ^a   Fina, Mariapaola ^a   Pellegrini, Cinzia ^a   Alinari, Lapo ^a   Derenzini, Enrico ^a   De Vivo, Antonio ^a   Sabattini, Elena ^a   Pileri, Stefano ^a   Baccarani, Michele ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b L and A Seràgnoli Hematology and Oncological Sciences Institute   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; PROTEINASE INHIBITOR; PYRAZINE DERIVATIVE;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER PATIENT; CANCER REGISTRY; CANCER REGRESSION; CANCER RELAPSE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CUTANEOUS T CELL LYMPHOMA; DEHYDRATION; DISEASE COURSE; DRUG ERUPTION; DRUG FATALITY; DRUG TOLERABILITY; FATIGUE; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; INFECTION; MALE; MULTIPLE CYCLE TREATMENT; MYCOSIS FUNGOIDES; NEUTROPENIA; ORTHOSTATIC HYPOTENSION; PERIPHERAL T CELL LYMPHOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SENSORY NEUROPATHY; THERAPY EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; MIDDLE AGED; PATHOLOGY; RECURRENT DISEASE; REMISSION; SKIN TUMOR; T CELL LYMPHOMA;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; FEMALE; HUMANS; LYMPHOMA, T-CELL; MALE; MIDDLE AGED; MYCOSIS FUNGOIDES; PROTEASE INHIBITORS; PYRAZINES; RECURRENCE; REMISSION INDUCTION; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 34948833649     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.11.4207     Document Type: Article

References (27)

1. Willemze R, Jaffe ES, Burg G, et al: WHO-EORTC classification for cutaneous lymphomas. Blood 105:3768-3785, 2005
2. Willemze R, Kerl H, Sterry W, et al: EORTC classification for primary cutaneous lymphomas: A proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood 90:354-365, 1997
3. Jaffe E, Nancy LH, Stein H, Vardiman JW (eds): Tumors of Hematopoietic and Lymphoid Tissues. Lyon, France, IARC, 2001
4. Zinzani PL, Magagnoli M, Bendandi M, et al: Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients. Ann Oncol 9:1351-1353, 1998
5. Zinzani PL, Baliva G, Magagnoli M, et al: Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: Experience in 44 patients. J Clin Oncol 18:2603-2606, 2000
6. Marchi E, Alinari L, Tani M, et al: Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: Phase II study of 32 patients. Cancer 104:2437-2441, 2005
7. Wollina U, Graefe T, Karte K: Treatment of relapsing or recalcitrant cutaneous T-cell lymphoma with pegylated liposomal doxorubicin. J Am Acad Dermatol 42:40-46, 2000
8. Wollina U, Dummer R, Brockmeyer NH, et al: Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma. Cancer 98:993-1001, 2003
9. Kuzel TM, Hurria A, Samuelson E, et al: Phase II trial of 2-chlorodeoxyadenosine for the treatment of cutaneous T-cell lymphoma. Blood 87:906-911, 1996
10. Trautinger F, Schwarzmeier J, Honigsmann H, et al: Low-dose 2-chlorodeoxyadenosine for the treatment of mycosis fungoides. Arch Dermatol 135:1279-1280, 1999
11. Kurzrock R, Pilat S, Duvic M: Pentostatin therapy of T-cell lymphomas with cutaneous manifestation. J Clin Oncol 17:3117-3121, 1999
12. Fierro MT, Doveil GC, Quaglino P, et al: Combination of etoposide, idarubicin, cyclophosphamide, vincristine, prednisone and bleomycin (VICOP-B) in the treatment of advanced cutaneous T-cell lymphoma. Dermatology 194:268-272, 1997
13. Akpek G, Koh HK, Bogen S, et al: Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophophamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma. Cancer 86:1368-1376, 1999
14. Chauhan D, Hideshima T, Mitsiades C, et al: Proteasome inhibitor therapy in multiple myeloma. Mol Cancer Ther 4:686-692, 2005
15. Orlowski RZ, Stinchcombe TE, Mitchell BS, et al: Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 20:4420-4427, 2002
16. Goy A, Younes A, McLaughlin P, et al: Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 23:667-675, 2005
17. O'Connor OA, Wright J, Moskowitz C, et al: Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 23:676-684, 2005
18. Izban KF, Ergin M, Qin JZ, et al: Costitutive expression of NF-kappa B is a characteristic feature of mycosis fungoides: Implications for apoptosis resistance and pathogenesis. Hum Pathol 31:1482-1490, 2000
19. Martinez-Delgado B, Melendez B, Cuadros M, et al: Expression profiling of T-cell lymphomas differentiates peripheral and lymphoblastic lymphomas and defines survival related genes. Clin Cancer Res 10:4971-4982, 2004
20. Nasr R, El-Sabban ME, Karam JA, et al: Efficacy and mechanism of action of the proteasome inhibitor PS-341 in T-cell lymphomas and HTLV-1 associated adult T-cell leukaemia/lymphoma. Oncogene 24:419-430, 2005
21. Sors A, Jean-Louis F, Pellet C, et al: Down-regulation constitutive activation of the NF-kappaB canonical pathway overcomes the resistance of cutaneous T-cell lymphoma to apoptosis. Blood 107:2354-2363, 2006
22. Carbone PP, Kaplan HS, Musshoff K, et al: Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 31:1860-1861, 1971
23. Cheson BD, Horning SJ, Coiffer B, et al: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas: NCl-Sponsored International Working Group. J Clin Oncol 17:1244-1253, 1999
24. Fleming TR: One-sample multiple testing procedure for phase II clinical trials. Biometrics 38:143-151, 1982
25. Machin D, Campbell MJ: Statistical tables for the design of clinical trials. Oxford, UK, Blackwell, 1987
26. A'Hern RP: Sample size tables for exact single-stage phase II designs. Stat Med 20:859-866, 2001
27. Kaye FJ, Bunn PA Jr, Steinberg SM, et al: A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med 321:1784-1790, 1989